Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

532 results about "Chemotherapy" patented technology

Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents) as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent (which almost always involves combinations of drugs), or it may aim to prolong life or to reduce symptoms (palliative chemotherapy). Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

Treatment of lung cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
Owner:BRISTOL MYERS SQUIBB CO

System for a head covering with integrated hair

Described herein is a head covering with integrated hair that is constructed to benefit the physical and emotional wellbeing of a person with hair loss due to, for example, chemotherapy. In one embodiment, the head covering includes a cap, a sweatband attached to the cap constructed and arranged to attach a hair piece to the cap, a crown portion forming a portion of the cap and configured to receive an attachment, and a brow pocket formed by the sweatband.
Owner:MELLETT III JAMES P

Systems and methods for use in emission guided radiation therapy

Described herein are systems and methods for positioning a radiation source with respect to one or more regions of interest in a coordinate system. Such systems and methods may be used in emission guided radiation therapy (EGRT) for the localized delivery of radiation to one or more patient tumor regions. These systems comprise a gantry movable about a patient area, where a plurality of positron emission detectors, a radiation source are arranged movably on the gantry, and a controller. The controller is configured to identify a coincident positron annihilation emission path and to position the radiation source to apply a radiation beam along the identified emission path. The systems and methods described herein can be used alone or in conjunction with surgery, chemotherapy, and / or brachytherapy for the treatment of tumors.
Owner:REFLEXION MEDICAL INC

Method and system for clustering transcriptome sequencing data

The invention provides a clustering method and system for transcriptome sequencing data. The method is applied to the technical field of data processing, and comprises the following steps: collecting cervical adenocarcinoma and para-carcinoma tissue specimens of a plurality of patients, and carrying out data preprocessing to obtain a standardized gene expression matrix; performing clustering operation on the standardized gene expression matrix based on a clustering analysis method combining a potential category model and sub-alliance division to obtain a clustered gene set; performing gene function annotation on the clustered gene set, and performing correlation analysis on a clustering result after function annotation and clinical characteristics of cervical adenocarcinoma to obtain correlation between gene expression and the clinical characteristics; and on the basis of clustering analysis and correlation analysis results, constructing a deep clustering prediction model based on a variational auto-encoder and a Gamma hybrid model so as to predict the prognosis risk or chemotherapy sensitivity of the patient. The problems that high-dimensional transcriptome data is poor in clustering stability and low in prognosis prediction precision are solved.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV +1

Application of coniferyl aldehyde and derivatives thereof in promoting hair regeneration and preventing alopecia

The invention belongs to the technical field of medicines, cosmetics and scalp care, and particularly relates to application of coniferaldehydes and derivatives or salts of the coniferaldehydes to preparation of medicines and cosmetics for promoting hair regeneration and treating chemotherapy-induced alopecia (CIA, CIA) and other types of alopecia, in particular to application of the coniferaldehydes and the derivatives or salts of the coniferaldehydes to preparation of the medicines and the cosmetics. Experimental results show that coniferyl aldehyde can promote hair regeneration of mice, accelerate hair growth of the mice and effectively relieve alopecia symptoms of the mice after chemotherapy, and the effect of coniferyl aldehyde is better than that of minoxidil. According to the application, coniferyl aldehyde or a composition thereof is given to a subject, so that the vigor of hair follicles is remarkably enhanced, the stationary period of the hair follicles is shortened, and the hair loss process is inhibited. The coniferyl aldehyde provided by the invention has the industrial application advantages of reliable biological safety, controllable preparation cost and high raw material accessibility, can be obtained by a plant extraction or chemical synthesis method, is suitable for an external solution, gel or a scalp care preparation, and provides a natural, safe and effective solution for alopecia patients.
Owner:EAST CHINA NORMAL UNIV

Core-shell structure drug-loaded magnetic-thermal hydrogel microsphere for treating drug-resistant ovarian cancer and preparation method thereof

The invention relates to a core-shell structure drug-loaded magnetic-thermal hydrogel microsphere for treating drug-resistant ovarian cancer and a preparation method thereof, belonging to the field of biological and medical micro-nano materials and technologies, and the core-shell structure drug-loaded magnetic-thermal hydrogel microsphere is formed by combining an inner core and a shell layer through covalent crosslinking and electrostatic interaction. An anti-tumor drug cis-platinum and magnetic nanoparticles are loaded on an inner core, and an AZ191 inhibitor is loaded on a chitosan shell, so that preferential release of AZ191 is realized to inhibit a drug-resistant signal channel and reduce the drug resistance of cancer cells, and the cis-platinum is slowly released after the action is completed to kill tumor cells. And the magnetic nanoparticles in the inner core can be heated under an external magnetic field, so that multifunctional synergistic treatment of magnetic hyperthermia, drug resistance inhibition and chemotherapy is realized. Chitosan and sodium alginate are biodegradable materials, so that the utilization rate of the embedded medicine can be increased, and meanwhile, the medicine can be metabolized out of a body. The preparation method does not relate to toxic cross-linking agents and organic solvents, and the prepared hydrogel core-shell microspheres have no biotoxicity. Complicated operation steps are not needed, the technological process is simple, the preparation period is short, and the application range is wide.
Owner:DALIAN UNIV OF TECH

High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data

PendingUS20250051848A1Microbiological testing/measurementDisease diagnosisColon rectal cancerEfficacy
The present disclosure generally relates to gene expression profiling of tissue samples obtained from colorectal cancer patients who are candidates for chemotherapy treatment. More specifically, the disclosure provides methods based on characterization of gene expression which allow a physician to predict whether a patient is likely to respond well to treatment with a chemotherapeutic reagent.
Owner:GEORGE MASON UNIVERSITY

Use of adrenoreceptor agonists in promoting hematopoietic regeneration

Provided herein are methods for promoting or inducing hematopoietic regeneration, or preventing or treating hematopoietic deficiencies, or treating or ameliorating aplastic anemia induced especially by a chemotherapy, or a radiation therapy, comprising administering an effective amount of an adrenoreceptor agonist, especially a selective β2 adrenoreceptor agonist or a selective β3 adrenoreceptor agonist or a nonspecific β adrenoreceptor agonist.
Owner:NAT INST OF BIOLOGICAL SCI BEIJING

Hyaluronic acid-based temperature-sensitive hydrogel SV-coated HP as well as preparation method and application of hyaluronic acid-based temperature-sensitive hydrogel SV-coated HP

The invention belongs to the field of biological pharmacy, and relates to a temperature-sensitive hydrogel, in particular to a temperature-sensitive hydrogel SV (at) HP based on hyaluronic acid as well as a preparation method and application of the temperature-sensitive hydrogel SV (at) HP. The temperature-sensitive hydrogel SV (at) HP entraps CS-siRNA nanoparticles and VEGF (at) PLGA microspheres, and is used for realizing microenvironment responsive drug delivery to treat intrauterine adhesion. Chlorogenic acid and TGF beta1 siRNA are self-assembled through disulfide bonds to form CS-siRNA nano-particles, the CS-siRNA nano-particles are used for treating intrauterine adhesion through gene and chemical therapy, and cell and animal experiments prove that the CS-siRNA nano-particles have a good effect of improving intrauterine adhesion. Through evaluation of a real-time fluorescence quantification method, a western blot method, a cell scratch experiment, laser confocal microscope observation, inverted fluorescence microscope observation, an in-vivo experiment and the like, the SV-coated HP gel has the effects of resisting inflammation, improving endometrial fibrosis, promoting IUA rat endometrial angiogenesis and repair, inhibiting intrauterine adhesion and improving the intrauterine environment.
Owner:HENAN UNIVERSITY

Photodynamic and chemotherapy synergistic antibacterial composite material as well as preparation method and application thereof

The invention provides a photodynamic and chemotherapy synergistic antibacterial composite material, the composite material comprises an intermediate composite material and hyaluronic acid HA coating the outer side of the intermediate composite material, and the intermediate composite material takes a photosensitizer i-ZnPPOPs as a substrate and is loaded with calcium peroxide and gentamicin. The composite material has excellent bacteria targeting characteristic and antibacterial effect. Specifically, hyaluronic acid can target hyaluronidase secreted by bacteria so as to capture the bacteria, and then the intermediate composite material is transferred to the surfaces of the bacteria and interacts with negatively charged bacterial membranes. Then, the exposed biomass-based CaO2 is released and reacts with water to generate H2O2 and O2, so that oxygen deficit of the infected wound surface is relieved, generation of < 1 > O2 in the i-ZnPPOPs is effectively promoted, and the photodynamic antibacterial effect is further improved. Meanwhile, the released gentamicin can further improve the antibacterial efficiency of the chemotherapy.
Owner:SHANDONG SHANWEI IMMUNOTECH CO LTD

Protein compositions for the treatment of inflammatory diseases

The present invention relates to the pharmaceutical compositions of lectin proteins and its use for the prevention, treatment and cure of inflammation, including inflammatory disease. The invention specifically relates to the pharmaceutical compositions for topical application comprising lectin proteins and its use for prevention, treatment and cure of inflammation due to chemotherapy and / or radiotherapy. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 70% homology to SEQ ID NO: 1.
Owner:UNICHEM LAB LTD

Nitrogen-containing derivatives of narasin, synthesis and uses thereof

The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and / or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and / or for preventing cancer recurrence and / or for decreasing resistance to a chemotherapy in a subject.
Owner:CENT NAT DE LA RECH SCI (C N R S) +2

Predicting response to neoadjuvant treatment in non-small cell lung cancer

The disclosure relates to methods of assessing the success of treatment with durvalumab and chemotherapy for resectable non-small cell lung cancer (R-NSCLC) in patients based on circulating tumor DNA (ctDNA) detection, ctDNA clearance and / or partial clearance and / or variant allele fraction (VAF) before and after such treatment. The disclosure also relates to methods for treating patients with R-NSCLC based on ctDNA detection, ctDNA clearance and / or partial molecular clearance and / or VAF before and after such treatment.
Owner:ASTRAZENECA AB

IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 / CXCR2 receptor inhibitors, useful in the treatment and / or prevention of chemotherapy-induced neuropathy, preferably in the treatment and / or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.
Owner:DOMPE FARMACEUTICI SPA

PDA in-situ polymerization drug perfusion delivery system and application thereof

According to the PDA in-situ polymerization drug perfusion delivery system provided by the invention, the interaction relationship of a perfusion drug system on an organism signal channel and immune response is studied; through manganese metal immunoregulation, based on copper death synergistic therapy, novel protein drug immunotherapy and enhancement of the inhibition action mechanism of traditional chemotherapy on bladder cancer cells, various drugs are organically combined by utilizing dopamine-mediated in-situ bladder intracavity polymerization loaded drugs and combining with the characteristics of polydopamine, so that the bladder cancer cell inhibition effect is enhanced, and the bladder cancer cell inhibition effect is enhanced. A novel multi-effect-in-one multifunctional bladder perfusion drug system is formed, the complexity of drug design is simplified, the bioavailability of drugs is improved, and it is ensured that multi-mode collaborative treatment in the bladder is achieved.
Owner:SOUTH CHINA HOSPITAL OF SHENZHEN UNIVERSITY

Quantitative assessment method for myocardial stress in breast cancer chemotherapy

InactiveCN120913845AHealth-index calculationCatheterPosterior myocardiumIV Chemotherapy
The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.
Owner:HUANGPU BRANCH OF THE NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE

Local chemotherapy device for esophageal cancer

PendingCN119524302AImprove local treatment effectprevent flowMedical devicesTopical treatmentOncology
The invention discloses an esophageal cancer local chemotherapy device, and belongs to the technical field of chemotherapy auxiliary equipment, the esophageal cancer local chemotherapy device comprises a sealing device, the sealing device comprises a drug delivery tube, the lower end of the drug delivery tube is fixedly connected with a zigzag mounting tube, and the side wall of the zigzag mounting tube is rotatably connected with a plurality of hinge connecting rods; the lower end of the zigzag mounting tube is fixedly connected with a closed collecting film fixedly connected with the upper ends of the hinge connecting rods, the interior of the zigzag mounting tube is slidably connected with a movable block, and the device can be tightly attached to the inner wall of the esophagus through unfolding of the closed collecting film to form an effective closed structure, so that the position of medicine at the focus is locked, and the medicine is prevented from being damaged. Therefore, the local treatment effect of the medicine can be improved, meanwhile, the medicine is prevented from flowing to the stomach along with natural physiological movement of the esophagus, stimulation to the digestive tract of a patient is reduced, meanwhile, the influence on normal tissue of the patient is reduced, precise treatment is achieved, and the health of the patient is protected to the maximum extent.
Owner:THE FOURTH HOSPITAL OF HEBEI MEDICAL UNIVERSITY (HEBEI CANCER HOSPITAL)

Culture system, culture method and application of gastrointestinal tumor chemotherapy drug-resistant organoid

The invention discloses a culture system, culture method and application of gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system comprises: a basic culture medium, which is a DMEM / F12 culture medium, and is additionally added with a special growth promoting factor obtained from a natural extract; the multiple growth factors comprise an epidermal growth factor (EGF), a fibroblast growth factor (FGF), a bone morphogenetic protein (BMP) and a vascular endothelial growth factor receptor inhibitor (VEGFRi), and the concentration of each growth factor is accurately screened and optimized; the extracellular matrix is Matrigel modified by physical and chemical methods; the specific additive comprises an antioxidant N-acetylcysteine (NAC). According to the culture system, the culture method and the application of the gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system which is closer to a real environment in vivo is constructed by optimizing basic culture medium components, setting various growth factors and specific additive concentrations and adopting modified Matrigel as an extracellular matrix.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

Pharmaceutical composition for treating liver cancer

The invention relates to the technical field of biological medicines, and provides a pharmaceutical composition for treating liver cancer, which is prepared from the following raw material medicines in parts by weight: 3 to 8 parts of radix paeoniae rubra, 1 to 3 parts of fructus sophorae, 3 to 10 parts of rhizoma polygoni cuspidati, 3 to 20 parts of spica prunellae, 3 to 20 parts of herba hedyotidis diffusae, 3 to 10 parts of herba violae, 2 to 5 parts of turtle shell, 1 to 5 parts of radix angelicae sinensis, 1 to 3 parts of rhizoma curcumae, 1 to 3 parts of apios fortunei maxim and 3 to 5 parts of fructus polygoni orientalis. According to the technical scheme, the problems that in the prior art, after radiotherapy and chemotherapy are conducted on patients, obvious side effects can be generated, such as the symptoms of inappetence, nausea and vomiting, diarrhea, stomachache, dental ulcer and the like, and some patients have the symptoms of listlessness, weakness, shortness of breath, alopecia and the like are solved.
Owner:HANGZHOU ZHONGFUTANG TRADITIONAL CHINESE MEDICINE HOSPITAL CO LTD

Combination therapies with ULBP2 targeting antibodies for treating cancers

PCT designated stage expiredWO2025085512A1Organic active ingredientsInorganic active ingredientsSquamous cancerULBP2
The present disclosure provides anti-ULBP2 antibodies or antigen binding fragments thereof, including bispecific. The antibodies are administered in combination with a chemotherapy agent, a radiation therapy, and / or an immune checkpoint inhibitor for treatment of basal squamous cancer. The present disclosure also relates to methods and kits for detecting a predisposition to, determining the risk of, and guiding therapy for ULBP2 related disorders.
Owner:EVOLVEIMMUNE THERAPEUTICS INC +1

Extracellular vesicles for therapy

This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). This disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and / or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.
Owner:LEKSUM LLC

Gastrointestinal tumor chemotherapy risk scoring model and construction method thereof

The invention relates to the technical field of gastrointestinal tumor chemotherapy risk assessment, and particularly discloses a gastrointestinal tumor chemotherapy risk scoring model and a construction method thereof, and the method comprises the steps: obtaining the individualized feature data and basic physiological data of a historical patient, and constructing an individualized difference library with a unique ID, and a core influence library; the method comprises the following steps: standardizing and coding double-library data, synchronizing clinical data containing treatment effect codes, forming a data dictionary, acquiring and coding current gastrointestinal tumor patient data, and matching the data dictionary to judge individual difference abnormity; when the first data set is abnormal, constructing a first data set, screening core independent variables through Logistic regression, and constructing a scoring model by using an LSTM (Long Short Term Memory) model; when no abnormity exists, redundant codes are removed to obtain a second data set, and modeling is conducted through the same method. Through double-library linkage and scene-divided modeling, the three-level toxicity risk prediction precision is improved, data support is provided for clinical chemotherapy dose adjustment and toxicity prevention, and the risk of excessive treatment or insufficient treatment is reduced.
Owner:FIRST AFFILIATED HOSPITAL OF GANNAN MEDICAL UNIV

BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss

Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1

Intelligent device for relieving side effects of radiotherapy and chemotherapy through pulse acupoint electrode stimulation

The invention discloses an intelligent pulse acupoint electrode stimulation radiotherapy and chemotherapy side effect relieving device, and relates to the technical field of medical auxiliary equipment, the intelligent pulse acupoint electrode stimulation radiotherapy and chemotherapy side effect relieving device comprises a machine body and an electric pulse therapeutic apparatus main body, one side of the electric pulse therapeutic apparatus main body is provided with two sockets, and two connectors are movably inserted into the two sockets; one ends of the two connectors are connected with four electrode patches through two connecting wires. According to the device for relieving side effects of radiotherapy and chemotherapy through intelligent pulse acupoint electrode stimulation, by arranging an intelligent limiting anti-falling mechanism, stable limiting of one or two connectors is achieved, and the problem that in the using process of an existing electric pulse therapeutic instrument device, the existing electric pulse therapeutic instrument device is not prone to falling off is solved. In the prior art, a connecting port on an electric pulse therapeutic apparatus is often connected with a connecting wire through a connector in an inserted manner, but the connecting wire is easy to loosen and fall off from the electric pulse therapeutic apparatus due to pulling, friction or vibration of an external force in the therapeutic process of a user, and the therapeutic continuity is further influenced.
Owner:ZHANGJIAGANG FIRST PEOPLES HOSPITAL

Traditional Chinese medicine composition and traditional Chinese medicine compound essential oil for relieving side effects of chemotherapy as well as preparation method and application of traditional Chinese medicine compound essential oil

The invention provides a traditional Chinese medicine composition for relieving chemotherapy side effects, traditional Chinese medicine compound essential oil and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 1-9 parts of pericarpium citri reticulatae, 1-9 parts of pericarpium citri reticulatae viride, 1-9 parts of clove, 1-9 parts of fennel, 1-9 parts of ginger, 1-9 parts of pogostemon cablin and 1-9 parts of rhizoma atractylodis. The traditional Chinese medicine composition is mainly used for treating abdominal distension pain, nausea and vomiting caused by damp turbidity resistance and spleen and stomach disharmony through the effects of promoting qi circulation, removing dampness, strengthening the spleen and harmonizing the stomach. Experimental results show that the traditional Chinese medicine compound essential oil prepared from the traditional Chinese medicine composition can reduce allotriophagia behaviors of rats and improve ingestion and drinking habits, has a recovery effect on metabolite disorder caused by chemotherapy-related nausea and vomiting, and provides a theoretical basis for a supplementary treatment method of chemotherapy-related nausea and vomiting.
Owner:MACAU HEAN XIANGYU APPLICATION RESEARCH INSTITUTE CO LTD

Use of tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy effectiveness in cancer treatment

Disclosed herein are methods of treating an individual having a cancer, of treating or identifying an individual having cancer for a treatment, or stratifying individuals having a cancer for a treatment based on a tumor mutational burden (TMB) score or a TMB score and a microsatellite instability assessment.
Owner:FOUNDATION MEDICINE INC

Intraluminal local drug delivery

Devices, systems and methods for localized delivery of a chemotherapy, hormonal therapy or targeted drug / biologic therapy to a target tissue area of an internal body organ of a patient. A catheter forms a sealed treatment chamber in a natural lumen extending through the target tissue area. Air is purged from the chamber, which is then filled with a liquid drug solution for an adequate treatment session time, solution volume and drug concentration to saturate the target tissue area, thereby providing the treatment. The drug concentration in the liquid soaking solution may be formulated to approximate the known maximum plasma concentration achieved during systemic delivery of the same drug. An integrated pressure relief circuit may be included to avoid unsafe pressure levels in the isolated chamber. The chamber is evacuated at the end of the treatment session.
Owner:ISOLA THERAPEUTICS INC

Tumor mineralization-inducing phosphorus-containing dendrimer / protein compound loaded with tirapazamine as well as preparation method and application of tumor mineralization-inducing phosphorus-containing dendrimer / protein compound

The invention relates to a tirapazamine-loaded phosphorus-containing dendrimer / protein compound for inducing tumor mineralization as well as a preparation method and application thereof, the compound takes diphosphonate-terminated phosphorus-containing dendrimer AK176 as a carrier, and the carrier is loaded with protein and medicine. The nano-drug can target tumor cells through FN and form a biomineralization layer in the peripheral area of tumor tissues, and a tumor hypoxic microenvironment is intensified, so that the pharmaceutical activity of tirapazamine is activated, and cooperative treatment of blocking treatment / chemotherapy of triple-negative breast cancer is realized.
Owner:DONGHUA UNIV